OR4A15 Antibody

What is OR4A15 and why is it studied in research?

OR4A15 (Olfactory Receptor Family 4 Subfamily A Member 15) is a human protein belonging to the G protein-coupled receptor (GPCR) superfamily, specifically classified within the Class O2 (tetrapod specific odorant) Odorant receptors family 4 . It is also known by alternative names including "Olfactory receptor 4A15" and "Olfactory receptor OR11-118" . This receptor consists of 7 transmembrane domains characteristic of GPCRs and plays a role in olfactory signal transduction pathways. The protein has a UniProt Primary accession number of Q8NGL6 and secondary accession numbers Q6IFL4 and Q96R65 . Researchers study OR4A15 to understand olfactory receptor function, GPCR signaling mechanisms, and potential roles beyond traditional olfaction. The availability of specific antibodies enables researchers to detect and study this protein's expression, localization, and function in various experimental contexts.

What applications is the OR4A15 antibody suitable for?

The OR4A15 antibody has been validated and tested for multiple laboratory applications, making it versatile for various experimental approaches. Specifically, this antibody is suitable for Enzyme-Linked Immunosorbent Assay (ELISA), Western Blot (WB), and Immunofluorescence (IF)/Immunocytochemistry (ICC) . Each application has recommended dilution ranges that have been empirically determined: for Western Blot applications, dilutions between 1:500-1:3000 or 1:500-1:2500 are suggested; for Immunofluorescence/Immunocytochemistry, dilutions of 1:100-1:500 are recommended; and for ELISA, a dilution of 1:10000 is typically optimal . Researchers should note that these are general guidelines, and optimal dilutions may need to be determined experimentally for specific research conditions.

What are the key characteristics of the available OR4A15 antibodies?

The OR4A15 antibody is a polyclonal antibody produced in rabbits using an immunogen consisting of a synthesized peptide derived from the C-terminal region of human OR4A15 . This antibody demonstrates specific reactivity to human OR4A15 and is provided in liquid form at a concentration of 1 mg/ml . The antibody is purified from rabbit antiserum using affinity chromatography with epitope-specific immunogen, ensuring high specificity . It is classified as an IgG isotype and is supplied in unconjugated form in a buffer consisting of PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02% sodium azide, and 50% glycerol . These characteristics make it suitable for numerous research applications while maintaining stability during storage and use.

What are the recommended storage conditions for OR4A15 antibody?

To maintain the activity and stability of the OR4A15 antibody, proper storage conditions are essential. The antibody should be aliquoted upon receipt to avoid repeated freeze/thaw cycles and stored at -20°C . Multiple freeze/thaw cycles can lead to protein denaturation and loss of antibody activity, so it is recommended to prepare small working aliquots rather than repeatedly thawing and refreezing the original vial. The addition of 50% glycerol in the buffer formulation helps prevent freezing damage and maintains antibody stability during storage . When handling the antibody, researchers should minimize exposure to room temperature and return unused portions to -20°C as quickly as possible to preserve activity.

How does the polyclonal nature of OR4A15 antibody impact experimental design and interpretation?

What optimization strategies should be employed for Western Blot applications using OR4A15 antibody?

Optimizing Western Blot protocols for OR4A15 detection requires careful consideration of several technical parameters. The recommended dilution range of 1:500-1:3000 provides a starting point, but researchers should conduct titration experiments to determine the optimal concentration for their specific samples . Since OR4A15 is a transmembrane protein with 7 transmembrane domains, proper sample preparation is critical for accurate detection . Consider these optimization strategies:

• Sample preparation:

  • Use specialized lysis buffers containing appropriate detergents (e.g., Triton X-100, NP-40, or CHAPS) to efficiently solubilize the membrane-bound receptor

  • Avoid excessive heating of samples (>70°C) which can cause membrane protein aggregation

  • Include protease inhibitors to prevent degradation

• Gel selection and transfer:

  • Use gradient gels (4-20%) to effectively resolve the receptor (expected molecular weight based on the 328 amino acid sequence )

  • Consider wet transfer with low SDS concentration in the transfer buffer to improve transfer efficiency of hydrophobic membrane proteins

• Blocking and antibody incubation:

  • Test different blocking reagents (5% non-fat milk vs. 3-5% BSA) to determine optimal signal-to-noise ratio

  • Extend primary antibody incubation time (overnight at 4°C) to enhance sensitivity

  • Include 0.05-0.1% Tween-20 in washing steps to reduce background

• Detection optimization:

  • Compare chemiluminescent substrates of varying sensitivity

  • Consider using signal enhancers specifically designed for membrane proteins

These strategies should be systematically tested and documented to establish a reproducible protocol for OR4A15 detection in Western Blot applications.

What are the critical considerations for immunofluorescence experiments using OR4A15 antibody?

When conducting immunofluorescence experiments with OR4A15 antibody, several critical factors must be addressed to obtain reliable and interpretable results. The recommended dilution range of 1:100-1:500 provides initial guidance, but optimization is essential for each experimental system . Consider these methodological considerations:

• Fixation and permeabilization:

  • Compare different fixation methods (4% paraformaldehyde, methanol, or combination protocols) to determine which best preserves OR4A15 epitopes while maintaining cellular architecture

  • Evaluate permeabilization reagents (0.1-0.5% Triton X-100, 0.1-0.5% Saponin, or 0.1% Tween-20) and durations to ensure sufficient access to the C-terminal epitope while preserving membrane structure

• Antigen retrieval:

  • For tissue sections or challenging samples, test antigen retrieval methods (citrate buffer pH 6.0 or Tris-EDTA pH 9.0) to expose masked epitopes

  • Optimize retrieval temperature and duration based on sample type

• Background reduction:

  • Include additional blocking steps with normal serum from the secondary antibody host species

  • Use diluents containing 0.1-0.3% Triton X-100 and 1-3% BSA to reduce non-specific binding

  • Consider autofluorescence quenching methods for tissues with high background (e.g., Sudan Black B treatment)

• Controls and validation:

  • Include peptide competition controls using the immunizing peptide derived from the C-terminal of OR4A15

  • Implement secondary-only controls to assess non-specific binding of the detection system

  • Consider counterstaining with markers for subcellular compartments to confirm expected localization patterns

These methodological considerations should be systematically evaluated to establish optimal protocols for detecting OR4A15 in different cellular contexts using immunofluorescence techniques.

How can specificity of OR4A15 antibody be validated in experimental systems?

Validating antibody specificity is crucial for generating reliable data, particularly for members of large protein families like olfactory receptors. For OR4A15 antibody, a multi-faceted validation approach is recommended:

• Genetic validation approaches:

  • Utilize CRISPR/Cas9-mediated knockout of OR4A15 as a negative control

  • Compare signal between wild-type cells and those with OR4A15 gene deletion

  • Employ overexpression systems with tagged OR4A15 constructs to confirm co-localization with antibody staining

• Biochemical validation:

  • Perform peptide competition assays using the C-terminal peptide immunogen

  • Conduct immunoprecipitation followed by mass spectrometry to confirm target identity

  • Test for cross-reactivity with recombinant proteins of closely related olfactory receptors, particularly other members of the OR4A subfamily

• Orthogonal detection methods:

  • Compare protein detection with OR4A15 mRNA expression using RT-PCR or in situ hybridization

  • Utilize multiple antibodies targeting different epitopes of OR4A15 when available

  • Implement proximity ligation assays (PLA) to verify interaction partners predicted for OR4A15

• Application-specific validation:

  • For Western blot, confirm that the detected band migrates at the expected molecular weight

  • For immunofluorescence, verify subcellular localization consistent with a transmembrane GPCR

  • Document batch-to-batch consistency through standardized validation protocols

This systematic validation approach ensures that experimental observations can be confidently attributed to OR4A15 rather than non-specific interactions or cross-reactivity with related proteins.

What buffer modifications might improve OR4A15 antibody performance in challenging applications?

The buffer composition can significantly impact antibody performance, especially when working with challenging samples or applications. The standard buffer for OR4A15 antibody (PBS without Mg2+ and Ca2+, pH 7.4, 150 mM NaCl, 0.02% sodium azide, 50% glycerol) provides baseline stability , but modifications may enhance performance in specific contexts:

• For enhanced signal in Western blotting:

  • Add 0.1-0.5% non-ionic detergents (Triton X-100 or Tween-20) to reduce non-specific binding

  • Include 1-5% BSA or casein as carrier proteins to stabilize the antibody

  • Test different pH ranges (7.2-8.0) to optimize antibody-epitope interaction

• For improved immunoprecipitation efficiency:

  • Reduce salt concentration to 100-120 mM NaCl to promote antibody-antigen binding

  • Add 0.1% digitonin or CHAPS for membrane protein solubilization while maintaining native conformation

  • Include protease inhibitor cocktails to prevent target degradation during extended incubations

• For challenging immunofluorescence applications:

  • Test Tris-buffered saline (TBS) as an alternative to PBS for reduced background

  • Add 1-5 mM EDTA to sequester trace metals that might interfere with binding

  • Include 0.1-1% normal serum from the same species as the sample to block non-specific interactions

• For flow cytometry applications:

  • Add 2-5 mM EDTA to prevent cell aggregation

  • Include 0.5-2% serum to reduce non-specific binding

  • Test the addition of 0.1% sodium azide for extended incubation periods

Researchers should systematically evaluate these modifications to identify optimal conditions for their specific experimental system and document improvements in sensitivity, specificity, or reproducibility.

How should researchers address weak or inconsistent signal when using OR4A15 antibody?

When encountering weak or inconsistent signals with OR4A15 antibody, a systematic troubleshooting approach should be implemented:

• Antibody dilution and incubation optimization:

  • Test a range of concentrations narrower than the recommended 1:500-1:3000 for Western blot or 1:100-1:500 for immunofluorescence

  • Extend primary antibody incubation time (overnight at 4°C or up to 48 hours for tissue sections)

  • Evaluate temperature effects by comparing 4°C vs. room temperature incubation

• Sample-related considerations:

  • Assess target protein abundance through preliminary experiments (e.g., RT-PCR for OR4A15 mRNA)

  • For tissues or cells with low expression, increase sample loading or implement signal amplification methods

  • Verify that sample preparation methods preserve the C-terminal epitope of OR4A15 recognized by the antibody

• Detection system enhancement:

  • Upgrade to higher-sensitivity detection systems (e.g., enhanced chemiluminescence substrates, TSA amplification for IF)

  • For immunofluorescence, use brighter fluorophores or try enzymatic detection methods

  • Ensure secondary antibody compatibility and freshness

• Technical optimization:

  • For Western blots, optimize transfer conditions for transmembrane proteins (longer transfer times, specialized buffers)

  • For immunofluorescence, enhance permeabilization to improve antibody access to the C-terminal epitope

  • Implement antigen retrieval methods if working with fixed or embedded samples

By systematically evaluating these parameters and documenting results, researchers can identify the limiting factors affecting OR4A15 detection sensitivity and develop optimized protocols for consistent results.

What strategies can be employed to study OR4A15 interaction with other proteins?

Investigating protein-protein interactions involving OR4A15 requires specialized approaches that accommodate the challenges of working with a 7-transmembrane GPCR . Consider these methodological strategies:

• Co-immunoprecipitation approaches:

  • Use mild detergents (0.5-1% digitonin, 0.5-1% CHAPS, or 1% DDM) to solubilize OR4A15 while preserving protein-protein interactions

  • Consider crosslinking with membrane-permeable reagents (DSP or formaldehyde) prior to lysis to stabilize transient interactions

  • Implement stringent controls including IgG pulldowns and reciprocal co-IP with antibodies against predicted interaction partners

• Proximity-based interaction detection:

  • Utilize BioID or APEX2 proximity labeling by generating OR4A15 fusion constructs

  • Implement FRET or BRET approaches using fluorescent or bioluminescent fusion proteins

  • Apply proximity ligation assays (PLA) with the OR4A15 antibody and antibodies against candidate interacting proteins

• Functional interaction studies:

  • Assess G-protein coupling through GTPγS binding assays or BRET-based G protein activation sensors

  • Investigate β-arrestin recruitment using enzyme complementation assays

  • Explore functional modifications (phosphorylation, ubiquitination) in response to receptor activation

• Structural biology approaches:

  • Consider native PAGE combined with Western blotting to detect stable complexes

  • Implement Blue Native PAGE to preserve membrane protein complexes

  • Explore crosslinking mass spectrometry (XL-MS) to identify interaction interfaces

These approaches should be tailored to the specific research questions and combined with appropriate controls to distinguish specific interactions from technical artifacts when studying OR4A15 protein interactions.

What considerations are important when selecting positive and negative controls for OR4A15 antibody validation?

Proper control selection is critical for rigorous validation of OR4A15 antibody specificity and performance. Researchers should implement the following control strategy:

• Positive controls:

  • Identify tissues/cell lines with documented OR4A15 expression (e.g., olfactory epithelium)

  • Generate transient overexpression systems using OR4A15 cDNA expression constructs

  • Consider creating stable cell lines with inducible OR4A15 expression for consistent positive controls

  • Use epitope-tagged OR4A15 constructs with commercial tag antibodies as orthogonal detection method

• Negative controls:

  • CRISPR/Cas9-mediated knockout cell lines lacking OR4A15 expression

  • siRNA or shRNA-mediated knockdown of OR4A15 (partial reduction should result in proportional signal decrease)

  • Tissues/cell lines documented to lack OR4A15 expression

  • Pre-immune serum controls to assess non-specific binding from the host species

• Specificity controls:

  • Peptide competition assays using the C-terminal peptide immunogen (should abolish specific signal)

  • Testing against related odorant receptors, particularly those in the OR4A subfamily

  • Secondary antibody-only controls to assess background from the detection system

  • Isotype-matched irrelevant primary antibody controls

• Technical validation controls:

  • Loading controls for Western blots (housekeeping proteins)

  • Cellular compartment markers for co-localization in immunofluorescence

  • Dose-response curves with recombinant protein to assess sensitivity and linearity

Implementation of this comprehensive control strategy will establish confidence in the specificity and reliability of results obtained using the OR4A15 antibody across different experimental applications.

How can OR4A15 antibody be integrated into high-throughput or multiplex experimental approaches?

Incorporating OR4A15 antibody into high-throughput or multiplex experimental designs requires careful optimization and validation to maintain specificity while increasing throughput:

• Array-based applications:

  • Validate OR4A15 antibody performance in reverse-phase protein arrays (RPPA) by comparing with Western blot results

  • For tissue microarrays, optimize immunohistochemistry protocols including antigen retrieval methods specific for OR4A15 detection

  • Implement appropriate normalization and quantification methods to ensure comparability across samples

• Multiplex immunofluorescence approaches:

  • Test compatibility with other primary antibodies from different host species

  • Validate spectral separation when using multiple fluorophores

  • Implement sequential staining protocols with proper blocking between rounds if antibodies are from the same species

  • Consider tyramide signal amplification (TSA) for multiplexing antibodies from the same species

• Flow cytometry applications:

  • Optimize permeabilization protocols to access intracellular/transmembrane OR4A15 while preserving other surface markers

  • Validate antibody performance in multi-parameter panels through careful titration

  • Implement proper compensation controls when using multiple fluorophores

• High-content imaging:

  • Establish automated image acquisition and analysis workflows

  • Develop robust segmentation algorithms to quantify OR4A15 localization

  • Implement quality control metrics to identify and exclude technical artifacts

• Single-cell applications:

  • Validate compatibility with single-cell proteomics methods

  • Test performance in CyTOF/mass cytometry applications with appropriate metal conjugation

  • Optimize fixation and staining protocols for CITE-seq or related methods

These approaches should be systematically evaluated and validated against established single-parameter methods to ensure that multiplexing or high-throughput adaptation does not compromise the specificity or sensitivity of OR4A15 detection.